CHICAGO -- Switch maintenance with the PD-1 immune checkpoint inhibitor pembrolizumab (Keytruda) led to improved progression-free survival (PFS) following first-line chemotherapy in metastatic urothelial carcinoma, a phase II trial found.
In this exclusive video from the American Society of Clinical Oncology's annual meeting, 鶹ý spoke with investigator Matthew Galsky, MD, director of genitourinary medical oncology at the Tisch Cancer Institute at Mount Sinai in New York City, about the study findings and whether this strategy could play a role in this treatment setting.
Disclosures
Galsky reported stock or other ownership in Rappta Therapeutics; consulting or advisory relationships with Aileron Therapeutics, Astellas Pharma, AstraZeneca, BioMotiv, Bristol-Myers Squibb, Dendreon, Dracen, EMD Serono, Genentech, GlaxoSmithKline, Incyte, Inovio Pharmaceuticals, Janssen, Lilly, Merck, Novartis, Numab, Pfizer, and Seattle Genetics; and institutional relationships with various pharmaceutical companies. Study co-authors reported various relationships with industry.
Primary Source
American Society of Clinical Oncology
Galsky MD, et al "Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182" ASCO 2019; Abstract 4504.